Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) EPS (Weighted Average and Diluted) (2021 - 2025)

Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at $0.07 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 333.33% year-over-year to $0.07, compared with a TTM value of $0.0 through Dec 2025, up 100.84%, and an annual FY2025 reading of $0.0, up 100.87% over the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.07 at Xeris Biopharma Holdings, up from $0.0 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.07 in Q4 2025, with the low at -$0.44 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.15, with a median of -$0.12 recorded in 2024.
  • Year-over-year, EPS (Weighted Average and Diluted) decreased 22.22% in 2024 and then surged 333.33% in 2025.
  • Tracing XERS's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.44 in 2021, then surged by 77.27% to -$0.1 in 2022, then rose by 10.0% to -$0.09 in 2023, then soared by 66.67% to -$0.03 in 2024, then surged by 333.33% to $0.07 in 2025.
  • Per Business Quant, the three most recent readings for XERS's EPS (Weighted Average and Diluted) are $0.07 (Q4 2025), $0.0 (Q3 2025), and -$0.01 (Q2 2025).